TrialLeukemia & lymphoma2019

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

Jeff P Sharman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.